Lyvgen Biopharma Co.
Latest round
- Series C
Last raised
- Feb 2021
Total raised
- $30M
Investors
- 8
About Lyvgen Biopharma Co.
, Ltd focuses on developing innovative immuno-oncology therapeutics that activate the body’s immune response against tumors., Ltd is based in Shanghai, China, specializing in immuno-oncology therapeutics.Lyvgen Biopharma specializes in the development of innovative immuno-oncology therapeutics, focusing on tumor-targeted immune activation through a proprietary platform known as xLinkAb. The company's primary offerings include next-generation monoclonal antibodies such as LVGN6051, LVGN7409, and LVGN3616. LVGN6051 is designed to enhance the proliferation and cytotoxicity of antitumor immune cells by utilizing crosslinking-dependent CD137 agonistic activity, achieving an optimal efficacy and safety profile. LVGN7409 activates CD40 to promote tumor antigen presentation and enhance the immune response, effectively transforming the immune 'cold' tumor microenvironment into a more responsive state. LVGN3616 serves to block the PD-1 pathway, thereby amplifying immune responses against cancer.Lyvgen Biopharma engages in business transactions primarily through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. The revenue model involves revenue-sharing agreements and potential milestone payments connected to the advancement of their proprietary products through clinical trials and regulatory approvals. Flagship products such as LVGN6051 and LVGN7409 may be offered under specific pricing plans that reflect their unique applications in oncology treatment. The company is also targeting expansion into additional markets, particularly in Europe and North America, by 2023.
Who invested in Lyvgen Biopharma Co.
8 investors across 2 rounds
See all investors in Lyvgen Biopharma Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lyvgen Biopharma Co.
Who invested in Lyvgen Biopharma Co.?
Lyvgen Biopharma Co. has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lyvgen Biopharma Co. raised?
Lyvgen Biopharma Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Lyvgen Biopharma Co. last raise money?
Lyvgen Biopharma Co.'s most recent round on record is a Series C, in Feb 2021.
What does Lyvgen Biopharma Co. do?
, Ltd focuses on developing innovative immuno-oncology therapeutics that activate the body’s immune response against tumors.
Where is Lyvgen Biopharma Co. headquartered?
Lyvgen Biopharma Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Lyvgen Biopharma Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back healthcare specialists companies at Lyvgen Biopharma Co.'s stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series C
Raising like Lyvgen Biopharma Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.